Understanding gut changes during Campylobacter infection
Mucosal and Microbiota Changes During Acute Campylobacteriosis
Mayo Clinic · NCT03223077
This study looks at how a Campylobacter infection changes the gut and whether those changes can lead to long-term bowel problems like Irritable Bowel Syndrome in people who have had the infection.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Mayo Clinic (other) |
| Locations | 1 site (Rochester, Minnesota) |
| Trial ID | NCT03223077 on ClinicalTrials.gov |
What this trial studies
This observational study investigates how gastrointestinal infections caused by Campylobacter affect the gut microbiota and mucosal lining. Researchers aim to identify changes during acute infection that may indicate a risk for developing chronic bowel issues, such as Irritable Bowel Syndrome (IBS). The study focuses on individuals who have tested positive for Campylobacter enteritis and examines various factors that may contribute to post-infectious IBS. By analyzing gut bacteria and mucosal changes, the study seeks to enhance understanding of the relationship between acute infections and long-term gastrointestinal health.
Who should consider this trial
Good fit: Ideal candidates are individuals who have tested positive for Campylobacter enteritis and have not undergone abdominal surgery.
Not a fit: Patients with a history of IBS, inflammatory bowel disease, or recent gastroenteritis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify individuals at risk for developing chronic gastrointestinal disorders after infection.
How similar studies have performed: Other studies have shown that changes in gut microbiota can be linked to post-infectious IBS, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * No abdominal surgery (except appendectomy and cholecystectomy) * Stool culture or Polymerase chain reaction (PCR) positive enteritis with Campylobacter Exclusion Criteria: * History of IBS, Irritable Bowel Disease (IBD) (Crohn's disease or ulcerative colitis), microscopic colitis or celiac disease. * History of gastroenteritis in six months prior to Campylobacter enteritis * Pregnancy
Where this trial is running
Rochester, Minnesota
- Mayo Clinic — Rochester, Minnesota, United States (RECRUITING)
Study contacts
- Principal investigator: Madhusudan Grover, MBBS — Mayo Clinic
- Study coordinator: Margaret K Breen-Lyles, BS
- Email: Breen-Lyles.Margaret@mayo.edu
- Phone: 507-255-3520
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Irritable Bowel Syndrome, Post infectious